retatrutide for diabetes Delivers Significant Hemoglobin A1C Reduction, Weight Loss in Phase 3 Type 2 Trial Diabetes Dialogue: Retatrutide Reduces Body

Long-term use of GLP-1 receptor agonists is being actively studied, with many patients experiencing continued appetite control and weight stabilization over time

The most commonly reported adverse effects were gastrointestinal in nature , including: Nausea Vomiting Diarrhoea Constipation Decreased appetite These effects were generally mild to moderate in severity, most prevalent during dose escalation, and tended to diminish over time

No studies to date have specifically evaluated the use of CGM in patients with gastroparesis-associated diabetes

Gault, [email protected] This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

It is essential to consult with a healthcare professional before taking prescription medications for weight loss purposes to ensure safety and effectiveness

Water and sweat can loosen the patch, and patch ingredients may be unsafe during physical activity